NOS2 and Insulin resistance: Importantly, results obtained with Mergetpa are closely similar to those reported earlier in this model of insulin resistance after 1-week treatment with the B1R antagonist SSR240612 (Dias et al., 2010; Dias and Couture, 2012a,b) or with the selective inhibitor of iNOS 1,400 W (Haddad and Couture, 2016).